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Background: Allergic rhinitis is a chronic illness, affecting 10 to 40% of the worldwide population. Chinese herbal
medicines, the treatment of allergic rhinitis, adopted thousands of years in ancient China, has recently raised much
attention among researchers globally. This study evaluates the effects of two Chinese herbal formulae [Cure-allergic-rhinitis
Syrup (CS) and Yu-ping-feng San (YS)] in treating undergraduate nursing students with allergic rhinitis over a 3-month
follow-up, when compared to a placebo control group.
Methods: A double-blind, randomised controlled trial with repeated-measures, three-parallel-groups design was
conducted in a random sample of 249 participants recruited from one university in Hong Kong. After baseline
measurements, participants were randomly assigned to CS, YS, or placebo groups (n = 83 per group). The main
outcomes, including symptom severity, quality of life, and body constitution, were measured with self-administered
questionnaires at baseline and immediately, 1 and 3 months after the 4-week interventions.
Results: 240 participants completed the trial, with 9 (3.6%) drop-outs. The results of Generalised Estimating Equations
test followed by pairwise contrasts tests indicated that the participants who received CS showed significantly
greater reduction of symptoms (mean difference of CS vs. placebo = 26.13–34.55, P <0.0005) and improvements
in quality of life (mean difference of CS vs. placebo = 12.81–16.76, P <0.001), and body constitution in ‘Qi-deficiency’,
‘Yang-deficiency’, and ‘Inherited Special’ (mean difference of CS vs. placebo = 7.05–8.12, 7.56–8.92, and 4.48–8.10,
P = 0.01– < 0.0005, 0.001–0.004, and 0.01– < 0.0005, accordingly, at three post-tests). The participants who received YS
also indicated significant greater improvements in symptom severity, quality of life, and a few patterns of body
constitution when compared to the placebo group. However, its effects were lesser in strength (i.e., smaller effect
sizes), varieties of symptoms, and body constitution and sustainability over the 3 months.
Conclusions: The herbal formula CS was found effective to reduce symptoms and enhance quality of life in young
adults (nursing students) with allergic rhinitis in ‘Yang- and/or Qi-deficiency’ body constitution. Further controlled trials
of its effects in Chinese and/or Asians with allergic rhinitis in terms of socio-demographic, ethnic and illness
characteristics and a longer-term follow-up are recommended.
Trial registration: The trial has registered at ClinicalTrials.gov with an ID: NCT02027194 (3 January 2014).
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Allergic rhinitis (AR) is an allergic inflammation of the
nasal airway induced by allergens such as dust, animal
dander, or pollen. This illness imposes irritable symptoms
such as nasal blockage, running nose, and repeated sneez-
ing, and causes fatigue, sleep deprivation, and an inability
to concentrate [1]. About 40% of the world population is
affected by AR, which is expected to be more prevalent
due to global warming and poor air quality [2,3]. Prevent-
ive measures, such as avoiding exposure to allergens, and
pharmacological treatments, such as intranasal corticoste-
roids, can only be effective to control or reduce symptoms
of AR, but are not able to cure the illness [4]. In addition,
long-term medication use may result in a wide variety of
adverse effects, ranging from mild dizziness, pain, and fa-
tigue, to more serious headaches, palpitation, nose bleed-
ing, and nasal polyps, and even hypertension and other
cardiovascular problems [5]. As current treatments are
not curative and treatment compliance is often not satis-
factory [6], further research is essential to test an alterna-
tive treatment of AR with better curative or longer-term,
and on the other hand less adverse, effects. Chinese herbal
medicine (CM), which may produce possible curative
function to a variety of chronic illnesses, has recently
gained much interest and is increasingly tested and
adopted for the treatment of AR.
Similar to Western medicine, in CM, the clinical mani-
festations (signs and symptoms) are collected from patients
and interpreted for making diagnosis of a disease. However,
CM practitioners diagnose a disease and prescribe treat-
ment in terms of individual patterns of syndrome (‘Zheng’)
and body constitution, reflecting an individual’s overall
body condition [7]. Syndromes can be described as the
pathological characteristics that an individual presents in
response to the pathogens, allergens, or other undesirable
stimulations; whereas body constitution is used to describe
one’s overall physical and psychological condition [8]. Body
constitution and current health status of an individual can
be considered in terms of the balance between co-existing
‘Yin’ and ‘Yang’ (i.e., believed to be the physical form and
functioning of a human being with low or deficient and
high or excessive energetic qualities, respectively) and
‘Heat’ and ‘Cold’ conditions of his/her internal organs [8,9].
Therefore, ‘Yin’ (or ‘Cold’) in the body will become in ex-
cess when ‘Yang’ (or ‘Heat’) is lacking or deficient of en-
ergy, and vice versa. Treatments from the perspective of
CM aim at helping an individual regain his/her balance be-
tween ‘Yin’ and ‘Yang’.
Based on these principles of CM, treatments for people
with AR can be prescribed in consideration of their pat-
terns of body constitution (or ‘Zheng’) [10]; most of whom
have been identified as having two patterns of body con-
stitution. These patterns include ‘Qi-deficiency’ (i.e., lack
of energy, oxygen and blood to keep warm, and immunedefence against allergens) during an early stage of AR [11]
and ‘Yang-deficiency’ (i.e., unable to maintain normal
function of the internal organs) in later (chronic) stage of
the illness, particularly in their ‘Lung’ (respiratory), ‘Spleen’
(digestive), and ‘Kidney’ (excretory) organs [12]. Conse-
quently, people with AR usually present with ‘cold’ or ‘flu’-
like symptoms such as running nose, nasal congestion,
and sneezing. As such, it is believed that an application of
herbal medicine with ‘hot’ (‘Heat’) nature can strengthen
functions of the ‘Lung’, ‘Spleen’, and/or ‘Kidney’ organs,
thus alleviating the symptoms of AR and even curing the
illness [13]. Nevertheless, a minority of patients with AR
(<5%) can present with other patterns of body constitu-
tion, such as ‘Yin-deficiency’ with ‘Yang-hyperactivity’
[14], and thus require a different medicinal treatment
from the majority of those with ‘Qi-deficiency’ and
‘Yang-deficiency’ as described above. Seven randomised
controlled trials on the effects of Chinese herbal medi-
cinal treatment of AR [15-21] were performed between
2000 and 2013 (Table 1). Different methods of assess-
ment and evaluation on treatment outcomes (e.g., skin
and multiple allergen tests, Ear, Nose and Throat spe-
cialty assessment, and blood samples for serum IgE,
liver, and/or renal function tests) were used, mostly
from the approaches to Western medicine. However,
none of these trials adopted the ‘Zheng’ differentiation
for prescription of treatment and, consequently, the pre-
scribed Chinese herbal medicines varied greatly with
regards to type and dosage which may not have been ap-
propriate to the body constitution patterns presented by
the patients receiving the medication. In addition, a very
short-term follow-up of the treatment effects had been
conducted, ranging from immediately to four weeks after
completion of the treatment regimen. However, about half
of these trials [16-18], the treatment group using Chinese
herbal medicine reported non-significant improvements
in most of their clinical outcomes, particularly with
regards to symptom severity and health-related quality
of life, when compared to the placebo control group.
Yu-ping-feng San (YS), or its modified form, is one of
the common herbal medicinal formulae with a ‘hot’
(‘Heat’) nature, and is recommended for enhancing the
functions of the ‘Lung’ and ‘Spleen’ organs when treating
several types of respiratory diseases such as AR [22-24].
Two recent CM studies reported that people with AR
who received a 4-week YS treatment reported a signifi-
cant reduction of AR symptoms and serum IgE or aller-
gen reactivity at immediately and/or 2–4 weeks after
intervention [22,24]. Similar to the abovementioned con-
trolled trials [15-21], the YS could not consistently dem-
onstrate significant therapeutic effects on most of the
other clinical outcomes such as patients’ body constitu-
tion and quality of life, as well as its longer-term effects
(e.g., >8 weeks).
Table 1 Seven randomised controlled trials of herbal formulae for people with allergic rhinitis (2000–2013)





Yu-ping-feng San: Interviewed by Chinese medicine
practitioner and Western physician
35 (20 and 15 in treatment
and control group,
respectively)
2 weeks treatment Significant improvements in
clinical symptoms: sneezing,
itchiness, running nose, and
stuffiness, as well as quality
of life in terms of complexion
and sleep
Radix Ledebouriellae 5% Follow-ups at the 2nd, 5th,
and 7th week of treatment





Radix Glycyrrhizae 6% Outcomes:
Herba Centipede 23% Clinical symptom score,
Herba Menthae 16% Quality of life (ChQOL questionnaire)
Radix Paeoniae Alba 16% Blood test for RFT, LFT, haematological








Shi-Bi-Lin Zhao et al.,
(2009) [17]
Yu-ping-feng San: ENT specialist assessment 126 (both 63 in treatment
and control group)
4 weeks treatment (twice daily)
and 5 visits
Significant improvements in
symptom diary and severity,
and quality of life
Skin test for dust mite, mould, and
animal dander
Baseline measurement and
each week of intervention;
Saposhnikovia divaricata 7.5 g 18–65 years old
Double-blinded RCT, with
placebo controlBlood test for LFT and full blood
count
Outcomes: Medical overall assessment not
reached statistical significance
2 weeks follow-up after
intervention
Magnolia biondii Pamp 15 g Blood serum IgE, Eosinophil Cationic
Protein (ECP), symptom records,
medicine diary, quality of life (SF-36),
overall medical condition, and level
of compliance
Blood test for IgE and ECP
also not significant differenceXanthium Sibiricum Patrin ex
wider 7.5 g
Others:
Angelica dahurica 20 g
Gentiana scabra Bunge 5 g
Verbena officinalis L. 5 g
Bu-Zhong-Yi-qi-tang Yang & Yu,
(2008) [20]
Formula ‘BZYQT, included: Skin test and MAST dust mite 60 (36 and 24 in treatment
and control group, respectively)
3 months treatment (BZYQT &
Ping-wai-san) in powder form;
3 times/day after meal
Nasal score, IgE level, PGE2 and
LTC4 significantly decreased
immediately after interventionYu-ping-feng San:
Atractylodes macrocephala
Koidz 2.0 g























Nasal symptoms of Okuda and
co-workers (1984); blood test for
IgE, and measurement of E2 and
LTC4, and COX smRNAOthers
Panax ginseng C. A. Mey.
4.0 g
Citrus reticulate Blanco 2.0 g
Cimicifuga
foetida L. 1.0 g Angelica
dah0rica fisch. ex Hoffim 2.0 g
Bupleurum chinense DC 1.0 g
Glycyrrhiza uralensis Fisch 4.0 g
Ziziphus jujube Mill var. inermis
Rehd 2.0 g




Magnolia officinalis Rehd. Et
Wils 1.5 g
Citrus reticulate Blanco 1.0 g
Zingiber officinale Rosc 0.5 g
Ziziphus jujube Mill. var.
inermis Rdhd 0.5 g
Glycyrrhiza uralensis Fisch 1.0 g
Xin-Yi-San Yang et al.,
(2010) [21]
Yu-ping-feng San: Skin test for dust mite, mould
and animal dander
108 (62 and 38 in treatment
and placebo control group,
respectively)
3 months treatment (treatment
and placebo groups) powders
in capsule
Significant improvements in




test, nasal symptoms, nasal airflow
resistance, nostril dissection area,
and serum titer of IgE
18–64 years old RCT with
placebo controls

























Table 1 Seven randomised controlled trials of herbal formulae for people with allergic rhinitis (2000–2013) (Continued)
Rhizome of Liqusticum sinense
Oliva
Dried rhizomas of liqusticum
Wallichi Franch
Rhizomas of Cimicifuga foetida L.
Rhizomas of Akebia quinata
Decne
Biminne Hu et al.,
(2002) [18]
Yu-ping-feng San: Assessed by physician and skin test 58 (26 and 32 for treatment
and placebo control group,
respectively) 18–65 year old
Five capsules of herbal extract
for 12 weeks and 5 visits
Non-significant improvement
in symptom severity symptom
improvements in treatment
group and only sneezing was
significantly improved
Ledebouriella divaricata 460 g Outcomes:
Astragalus membranaceus 552 g Serum IgE, symptom diary with
visual analogue scale, quality of
life (RQLQ), patient evaluation
of symptom improvement, and
overall medical evaluation, and
level of compliance
RCT with placebo controls Baseline, interim and a few
weeks after treatments
Quality of life was significantly
improved
Others: One year later treatment
was offered to the placebo
(wait-list) controlsRehmannia glutinosa 460 g
Scutellaria baicalensis 460 g
Polygonatum sibiricum 368 g
Ginkgo biloba 460 g
Epimedium sagittatum 460 g
Psoralea corylifolia 460 g
Schisandra chinensis 368 g
Pulp of prunus mume 184 g





Yu-ping-feng San: Assessed by Western (ENT) and
Chinese medicine practitioners,
conforming the diagnosis of AR
55 (28 and 27 for treatment
and control group, respectively)
8 weeks of extract capsules Significant improvements in
symptom severity scores and
quality of life in treatment
group in the 8th and 10th
week





Saposhnikoviae, radix Outcomes: Subjects randomly allocated
by computer
Others: Nasal Symptom Quality of life
(RQLQ), amount of medication

































RCM-102 Lenon et al.,
2012 [16]
Yu-ping-feng San: Medical assessment by ENT
expert
95 (47/48) 8 weeks of treatment – two
capsules 3 times per day
(treatment and placebo
group)
No significant differences on
all outcomes
18–65 years oldAstragalus membranaceus (Fish.)
Outcomes:
Skin test, symptom severity,
quality of life, and blood test
for liver and kidney functions
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http://www.trialsjournal.com/content/15/1/261Another herbal medicinal formula termed Cure-allergic-
rhinitis Syrup (CS), which consists of three classical herbal
formula ‘Huang qi jian zhong tang’, ‘Li zhong tang’, and
‘Gui zhi tang’, has been used for over thousands of years
for the treatment of people with ‘Cold’ and ‘Qi-deficiency’
body constitution and weaknesses in ‘Lung’ and ‘Spleen’
organs, as well as in ‘Kidney’ [25], particularly those with
respiratory illnesses such as AR [26-28]. The CS is also
‘hot’ in nature and has been suggested to enhance the
functions of the ‘Lung’ and ‘Spleen’ organs, but also the
‘Kidney’, which all together are believed to be the main
reasons (‘roots’) of AR [27,28]. Therefore, people who
have been diagnosed with a ‘Qi-deficiency’ and/or ‘Yang-
deficiency’ body constitution (or ‘Zheng’) are considered
appropriate and beneficial to receive the CS treatment.
This study aimed to evaluate and compare the effective-
ness between two alternative herbal medicines, CS and
YS, and one placebo group for young adults (nursing stu-
dents) with AR on improving their AR symptoms (pri-
mary outcome), three ‘unhealthy’ patterns of body
constitution (‘Qi-deficiency’, ‘Yang-deficiency’, and ‘Inher-
ited special’), and health-related quality of life, over a
3-month follow-up. This double-blind controlled trial
was the first one in Chinese young adults with AR to
test the effectiveness of the two Chinese herbal medi-
cinal formulae on patient outcomes from the perspec-
tives of both Chinese and Western medicine (e.g., body
constitution and AR symptoms, respectively). The re-
search hypothesis for the primary outcome was that
the participants in the CS group and/or the YS group
would indicate a significant reduction of their AR symp-
tom severity than those in the placebo group immediately
and at 1 and 3 months after completion of their 4-week
treatments. Secondary hypotheses included that the CS
and/or the YS participants would indicate significant im-
provements in their health-related quality of life and/or
body constitution than those in the placebo group over
the 3-month follow-up. We would also like to test
whether the treatment effects of CS would be signifi-
cantly greater than those of YS or not.
Methods
This was a double-blind randomized controlled trial
with repeated-measures, three parallel groups (i.e., two
comparative treatment groups and one placebo control
group) design. A random sample of nursing students
considered one of the highly prevalent groups of AR was
recruited as subjects in this controlled trial. The nursing
students with AR who were assessed and found eligible
for inclusion (n = 249) and completed the baseline mea-
sures (T1) were randomly assigned into one of the three
study arms, including the Cure-allergic-rhinitis syrup
(CS), Yu-ping-feng San (YS), or placebo control group,
each consisting of 83 participants.Sample recruitment, medical assessments, prescrip-
tions, and outcome measurements and follow-ups were
performed at the Integrative Health Clinic of the Hong
Kong Polytechnic University serving for students, staff,
and visitors between April 2013 and February 2014.
Figure 1 shows the flow diagram of the controlled trial
procedure according to the revised version of the CON-
SORT statement [29], including subject enrolment, group
allocation, outcome measurements, follow-ups, and data
analyses.
Recruitment
Participants were randomly recruited from the bacca-
laureate degree nursing programmes at one of the three
universities with similar full-time undergraduate nursing
programmes (about 35% of the total nursing students) in
Hong Kong. There were about 2,000 full-time under-
graduate nursing students at the Hong Kong Polytechnic
University under study during recruitment. When at-
tending classes, the students who agreed to use CM and
participate in this study (n = 319) were asked to attend
medical assessment by a registered CM practitioner in
the Integrative Health Clinic. Those who met the study
criteria specified below (n = 249) were asked to complete
a written consent with full explanation of the study
procedure and were then grouped in terms of gender
and AR symptom severity (mild, moderate, and se-
vere). For each of the six groups of eligible subjects,
each student was asked to draw a labelled card (1 = CS,
2 = YS, and 3 = Placebo) from an opaque envelope and
was then allocated into the CS, YS, or placebo group
for the 4-week treatment.
Inclusion criteria of participants specified those full-
time undergraduate nursing students who were: (a) pre-
viously diagnosed with AR (seasonal or perennial) by a
Western or CM practitioner for >1 year with at least
one allergic history; (b) presenting a body constitution of
‘Qi-deficiency’ and/or ‘Yang-deficiency’, according to the
Chinese medicinal assessment at recruitment; (c) aged
18 or above; and (d) able to understand Cantonese or
Mandarin and the written Chinese language in the self-
reporting questionnaires. Exclusion criteria for the nurs-
ing students included those who: (a) presented a body
constitution of ‘Heat’ and/or ‘Yin-deficiency’ during the
CM assessment; (b) were currently receiving Chinese
and/or Western medications such as anti-hypertensive
and psychiatric drugs; (c) had any known medical his-
tory or co-morbidity of one or more acute or chronic
medical diseases, such as heart, liver, and lung dis-
eases, and mental disorders; (d) had recently received a
major operation, chemotherapy and/or radiotherapy,
or planned to be hospitalised over the study period;
and (e) had any known history of allergy to Chinese
herbal medicines.
All undergraduate Nursing students at The 
Assessed for eligibility by CMP 
(n=317)
Excluded (n=1570) from the study:
- Refused or not interested in study 
participation (n=113)
- Not eligible such as without any symptoms 
of AR (n=1457)
Not eligible, e.g., co-morbidity of other illness 
or not with Cold and Qi-Yang-Deficiency Body 
Constitution (BC) pattern (n=68)
Subject (n=249) with written consent 
Conducted pre-test (Time 1) and collected data on BC, QOL, AR severity, and demographics; and 
comprehensive health assessment 
Subject allocated into three study groups by stratified randomization in terms of gender and AR 
severity by the clinic nurse
Allocated to a 4-week Cure-
Allergic Rhinitis Syrup (n=83)
Allocated to a 4-week
Yu-ping-fung San (n=83)
Allocated to a 4-week
Placebo group (n=83)
Conducted an Interim assessment (end of the 2nd week) 
Performed Chinese medicinal assessment for adverse effects and comprehensive health assessment
Dropouts from the study (n=9; CS=2, YS=3, Placebo=4)
Conducted the 1st post-test (Time 2) immediately after the intervention (at the end of the 4th week)
on study outcomes, including BC, QOL, AR severity, and usage of current Western medicine
Performed comprehensive health assessment
Conducted the 2nd post-test (Time 3) at 1 month after the intervention on outcomes similar to Time 2 
Performed comprehensive health assessment
Conducted the 3rd post-test (Time 4) at 3 months after the intervention on outcomes similar to Time 2
Performed comprehensive health assessment
Included in data analysis (n=81)
Completed follow-up (n=80)
Declined F/U at post-tests 2 and 
3 (n=1) due to loss to contact
Included in data analysis (n=80)
Completed follow-up (n=79)
Declined F/U at post-tests 2 and
3 (n=1) due to loss to contact
Included in data analysis (n=79)
Completed follow-up (n=79)























Figure 1 A flow diagram of the procedure of this clinical trial. After confirming eligibility, 249 nursing students were recruited and randomly
assigned into one of the three study arms after completing the baseline measurements; 240 completed one to three post-tests over a 3-month
follow-up and finally only 9 dropped out during the treatment period.
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Sample size calculation was based on the average effect
sizes in two previous clinical trials of Chinese herbal
medicine for people with AR [21,30] on improving the
severity of AR symptoms (primary outcome), of 0.36
(ranging from 0.30 to 0.44), at one week after treatment,
when compared to the placebo group. With the level of
statistical significance set at 0.05 and a study power of
90% [31], an estimated sample size was 63 participants
per group (i.e., 226 nursing students in three study arms)
using the formula of Cohen’s d for repeated-measures
ANOVA test among three groups in GPower software
[32], taking account of a 20% potential attrition [21].
Hence, all of the students (n = 249) who met the study
criteria and agreed to participate were included because
they were similar to the estimated sample size calculated
for achieving a satisfactory power and statistical signifi-
cance in this study.Allocation and randomization
A stratified random sampling method from three groups
of eligible subjects in terms of symptom severity of AR
(mild, moderate, and severe) was adopted according to
the assessment and survey guideline of the World Health
Organization [33]. Each symptom severity group was fur-
ther subdivided into two subgroups in terms of gender be-
fore drawing a labelled card for group allocation. These
two characteristics were the potential confounding factors
of treatment effects in AR from the perspective of CM
[34]. The medical assessment, randomisation procedure,
and treatment allocation were performed by an independ-
ent clinic nurse, while the participants, assessor (trained
research assistant), and researchers were fully concealed
and blinded to the group assignment and treatment pro-
cedure. In order to maintain complete blinding, a clinic
nurse safely kept the participant list locked and, with as-
sistance from clinic staff, administered bottles of Chinese
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assignment.
Interventions
Two types of herbal medicine were prepared and bottled
by the researcher and kept in the refrigerator of the
clinic one day before use. The herbal and placebo medi-
cines were in syrup form due to better taste and absorp-
tion and user-friendliness. A very small amount of fresh
ginger (3 g) was added to the placebo medication to es-
tablish a spicy taste and smell and be able to exert sea-
soning but no treatment effect in AR [18,30]. With sugar
and wheat powder added to the herbal medicines, the
spicy taste and texture of the three kinds of syrups used
for all of the three study groups were very similar. This
similar form, colour, and route of administration of the
medication used among the three study groups was
beneficial to provide a consistent and standardized for-
mat of medicinal treatment in this trial, as well as high
levels of convenience and preference for people with
chronic AR disease. The same decoction method for the
CS, YS, and placebo medication included: (a) after the
cleansing procedure, boiling the herbal medicine with
2,000 mL of water for 2 hours to 500 mL of herbal con-
coction; (b) after cooling to room temperature, pouring
the 500 mL of herbal concoction into a glass bottle
(750 mL or 1,000 mL); and (c) labelling it as 1 (=CS), 2
(=YS), or 3 (=placebo) and storing it in a refrigerator (at
4°C). Each of the participants in the three study groups
was provided with one bottle of 500 mL herbal syrup
weekly for four weeks after a Chinese medicinal consult-
ation and assessment made in the clinic. A standard
spoon was offered to each participant to administerTable 2 Content and nature of 12 Chinese herbs in Cure-aller
Pharmaceutical name Chinese name Nature Flavour
Astragali Radix (6 g) 黃耆 Hyangqi Slight warm Sweet
Codonopsitis Radix (6 g) 黨参 Dan Shen Neutral Sweet
Atractylodis macrocephalae
Rhizoma (6 g)
白朮 Baizhu Warm Sweet bitt
Rhizoma Zingiberis (3 g) 乾薑 Ganjiang Warm Acrid bitte
Cinnamomi Ramulus (3 g) 桂枝 Guizhi Warm Acrid swe
Jujubae Fructus (12 g) 大棗 Dazap Warm Sweet
Aconitilaterali Radix
sPreparata (1.5 g)
熟附子 Fuzi Hot Acrid
Asari Radix et Rhizoma (0.6 g) 細辛 Xixin Warm Acrid
Magnoliae Flos (3 g) 辛夷 Xinyi Warm Acrid
Folium Artemisiae (3 g) 艾葉 Aiye Warm Bitter acrid
Triticum aestivum (3 g) 淮小麥 Neutral Sweat
Saccharum Granorum 飴糖 Yitang Warm Sweet70 mL of syrup once per day from the bottle to be di-
luted with half a cup of water. Participants could easily
transport the diluted syrup bottle to any school, extra-
curricular, or social activity at their own convenience.
The Cure-allergic-rhinitis Syrup [治敏膏] (CS) contained
12 herbal medicines with a ‘hot’ nature, based on three
classical herbal formulas – ‘Huang qi jian zhong tang’,
‘Li zhong tang’, and ‘Gui zhi tang’ [25]; its ingredients with
their respective functions are outlined in Table 2. The
composition and dosage of the CS were reviewed and ap-
proved by a group of experienced CM practitioners and
pilot tested in 20 young adults with AR by the researchers
with satisfactory therapeutic effects on symptom reduction
and no adverse effect noted during interim and post-
intervention assessments by two CM practitioners. The CS
had to be taken once daily (70 mL) over 4 weeks in this
study.
A modified form of Yu-ping-feng San [玉屏風散] (YS),
which contained six herbs previously used for treatment
of AR in recent CM studies [22-24], was adopted to be
an alternative medicinal treatment in this study. Similar
to CS, the majority of the contents of this herbal medi-
cation were also ‘hot’ in nature; its ingredients and their
functions are outlined in Table 3. Finally, the syrup for
the placebo control group contained wheat powder,
sugar, and a small amount of spicy-tasting fresh ginger,
thus having a similar taste and smell as the above two
herbal medicines used.
Progress of the participants in each treatment and
monitoring of their health condition was assured by in-
terim medical assessment by the same CM practitioner
by an appointment made at the individual’s convenience.
Problems with the progress of medication taken andgic-rhinitis Syrup (CS)
Acting organs Functions
Lung, spleen Reinforce Qi and strengthen body resistance
Lung, spleen Tonify the lung and spleen
er Spleen Reinforce Qi of the spleen
r Spleen, liver Re-warm the spleen
et Lung, heart Reinforce Qi and disperse cold
Spleen Reinforce Qi and digestive system and harmonise
different drugs
Spleen, kidney Reinforce Yang, expel ‘cold’ and release ‘flu’
syndrome
Lung, kidney Expel wind and cold, warm the lung, and
decrease nasal congestion
Lung Expel ‘cold’ and decrease nasal congestion
Spleen, kidney Warm the meridians and dispel ‘cold’
Heart, liver Soothe the liver and replenish Yin
Lung, spleen Strengthen and replenish the Qi of the spleen
Table 3 Content and nature of six Chinese herbs in Yuk-ping-feng San (YS)
Pharmaceutical name Chinese name Nature Flavour Acting organs Functions




白朮 baizhu Warm Sweet bitter Spleen Reinforce Qi of the spleen
Saposhnikoviae Radix (3 g) 防風 Fangfeng Slight warm Acrid Spleen, liver Expel wind-dampness and alleviate pain
Magnolia Flos (3 g) 辛夷 Xinyi Warm Acrid Lung, stomach Expel cold and decrease nasal congestion
Glycyrrhiza uralensis 甘草 Neutral Sweet Spleen, lung Reinforce Qi and harmonise all other herbs
Xanthii, fructus 蒼耳子 warm Acrid bitter Lung Release nose blockage and expel wind
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lected by the clinic nurse and discussed weekly among
the research team and CM practitioner. Strategies in im-
proving medication compliance and referrals to medical
consultation for any reported adverse effects were en-
couraged and clarified with individual students in need
of support. The participants also agreed not to inform
the assessor and CM practitioner at the clinic about
their study participation. Any queries on the study and
their treatment used would be first discussed with the
clinic nurse as needed.
Measures
Participants completed three outcome measures within
the questionnaires delivered by the research assistant
and returned to her at recruitment (T1), immediately
(T2), and at 1 (T3) and 3 months after completion of
their 4-week treatment. These measures included pat-
terns of body constitution with the Constitution in
Chinese Medicine Questionnaire (CCMQ), symptom se-
verity with the 10-cm visual analogue scales of the Rhi-
noconjunctivitis Quality of Life Questionnaire Standard
(RQLQ-S), and quality of life with the 7-point Likert
scales rated on items of the RQLQ-S.
Constitution in Chinese Medicine Questionnaire (CCMQ)
The 60-item CCMQ was developed by Wang et al. [35]
for evaluation of the patterns of body constitution and
consisted of nine patterns, including eight unhealthy pat-
terns, namely ‘Qi-deficiency’ (8 items), ‘Yang-deficiency’
(7 items), ‘Yin-deficiency’ (8 items), ‘Phlegm-dampness’
(8 items), ‘Dampness-heat’ (6 items), ‘Blood stasis’ (7
items), ‘Qi-depression’ (7 items), and ‘Inherited special’
(7 items), and one healthy ‘Gentleness’ (8 items). The
nine patterns of body constitution have been commonly
employed in assessment of patients with a variety of al-
lergic reactions [36]. The participants rated their level of
experienced symptoms over the past 7 days on a 5-point
Likert scale, ranging from ‘1 = No’ to ‘5 = All of the time’.
The total score of each pattern was calculated by addingup the scores of all items and subtracting the total number
of items in the pattern, then divided by to the total num-
ber of items multiplied with four, and finally transforming
into a percentage [35,37]. A higher percentage of the
transformed score in the eight unhealthy patterns indi-
cated a poorer health state, whereas a higher percentage
in the ‘Gentleness’ represented a better overall health
state. As the therapeutic effects of the CM treatment used
are mainly aimed at helping the participants with ‘Qi-defi-
ciency’, ‘Yang-deficiency’, and ‘Inherited special’, the out-
come evaluation was focused on these three unhealthy
patterns of body constitution in this study, as well as the
‘Gentleness’ indicating an overall healthy state of the
participants.
The CCMQ has demonstrated satisfactory face validity
and content validity (content validity index was 0.8) with
a group of CM experts [35]. In addition, the overall scale
and its subscales showed satisfactory concurrent validity
with SF-12 (Pearson’s r = 0.18–0.61, P <0.01), reproduci-
bility (kappa statistics ranged from 0.32–0.53), sensitivity
in predicting patterns of body constitution and CM diag-
noses (50%–75%), and internal consistency (Cronbach’s
alpha coefficients of 0.71–0.88), in 1,084 Hong Kong
Chinese people [38].Rhinoconjunctivitis quality of life questionnaire standard
(RQLQ-S) – visual analogue scales measuring symptom
severity
The 28-item RQLQ-S was modified from the original
RQLQ developed by Juniper and Guyatt [39] with fur-
ther testing on its validity in terms of symptom assess-
ment and standardization of the first three questions. It
consisted of seven domains, including symptoms in sleep
(3 items), nasal (4 items), non-nasal/eye (7 items), prac-
tical problems (3 items), activity limitation (3 items), eye
symptoms (4 items), and emotional function (4 items).
Severity of symptoms of AR was assessed by self-rating
on a set of 10-cm visual analogue scales, from a starting
point denoted ‘No symptom’ to a 10 cm end-point denoted
‘Extremely severe’. The RQLQ-S was sensitive to detect a
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change of 0.5 in mean total score of the RQLQ-S has been
considered a clinical significant change in one’s disease
condition of AR [40]. The RQLQ-S could also be applied
to assess different levels of symptoms of AR, including
mild to severe intermittent and persistent ones [41,42].
Rhinoconjunctivitis quality of life questionnaire standard
(RQLQ-S) – 7-point Likert scales measuring quality of life
The 28-item RQLQ-S was developed for evaluating the
health-related quality of life of people with AR [43]. As
mentioned above, in order to measure symptom severity
the respondents indicated their perceptions toward their
functional impairments in relation to AR over the past
7 days by rating on a 7-point Likert scale, ranging from
‘0 = None’ to ‘6 = Extremely’. With equal weighting on
each item, the total scores for both the total scale and its
seven subscales would be summed up from all of their
item scores [40]. A higher total score would indicate a
lower level of perceived quality of life. The scale has
demonstrated a very strong correlation (Pearson’s r = 0.86)
with the original RQLQ [39], and very satisfactory test-
retest reliability (Intra-class correlation of 0.99, P = 0.001)
and internal consistency (Cronbach’s alpha of 0.92) in
100 people with AR [43]. Its concurrent validity with
physical and mental domains of SF-36 was also satis-
factory (Pearson’s r = −0.35 and −0.47, respectively).
Demographic data sheet
Socio-demographic data (e.g., age, gender, education,
marital status, and family household income) and med-
ical history (e.g., duration of AR, current medical treat-
ment received and other co-morbidities) of the participants
were collected by using a demographic data sheet designed
by the researchers.
Data collection procedure
The potential subjects (nursing students) who showed
interest in this trial were assessed for their eligibility of
participation by a registered CM practitioner in the Inte-
grative Health Clinic of the University. For those eligible
to participate, they were approached by the research as-
sistant to explain the purpose and procedures of the
study and obtain the written consent. They were then
administered with three self-reporting questionnaires
(i.e., the CCMQ, the RQLQ-S with visual analogue
scales, and the RQLQ-S with 7-point Likert scales) and
the demographic data sheet as the baseline measurement
(T1). After completion of the questionnaires and being
randomly allocated to either one of the three groups by
drawing a labelled card, the clinic nurse administered a
bottle of herbal medicine to the participants according
to their assigned treatment. Participants returned to the
clinic once a week to collect a new bottle of herbalmedicine. At the second week, they received an interim
medical assessment by the registered CM practitioner to
monitor their treatment progress and detect any adverse
effects experienced.
After the 4th week of treatment, they returned to the
clinic thrice for follow-up assessment on the three treat-
ment outcomes (body constitution, symptom severity,
and quality of life) by completing the same set of ques-
tionnaires as T1, at immediately (T2, by the end of the
4th week), 1 month (T3), and 3 months (T4) after com-
pletion of their treatments. The participants were given
between 20 and 25 minutes to complete the question-
naires. During each outcome measurement and interim
assessment, they also received a comprehensive health
assessment by the researchers, including their vital signs
and oxygen saturation, peak flow rates to detect respira-
tory functioning and possible adverse effects of the treat-
ment received.
Ethical considerations
Ethical approval of this trial was obtained from the Human
Subjects Research Ethics Committee of the Hong Kong
Polytechnic University (Ref. No.: HSEARS20130111002).
Written informed consent was obtained from the respon-
dents after the study purpose and procedure had been fully
explained. If any illness and compliance problems were
found in any of these participants over the study period,
they were assessed by the CM practitioner and referred to
further medical advice if deemed necessary. Students were
reminded of reporting any discomfort and co-morbid ill-
ness, if any, and encouraged to ask any questions about the
study. They were given the emergency contact telephone
of the clinic nurse and a researcher and were referred to
Western and Chinese medical consultation as needed.
The herbal medicine selection was double-checked by
an independent registered CM practitioner and medicinal
formation was agreed by at least another two medical
practitioners. Any toxic effect of the herbal medicines
used was minimised by the optimal boiling time and low
dosage. Although there would be very low risk for adverse
events (<0.01%) [22], comprehensive health assessments
were provided at baseline, interim assessment, and three
post-tests for each of the participants to monitor their
health parameters such as vital signs, body weight, and
urine for routine test to detect any possible adverse effects
of the herbal medicines used.
Data analysis
Pre- and post-test data collected from the two treatment
groups and the placebo group were numerically coded
and analysed using the IBM SPSS for Windows, version
20. Goodness-of-fit χ2 test was used to test any differ-
ences in the demographic characteristics between the
three groups. Mean score differences on the outcome
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groups using one-way analysis of variance test. Final data
analysis based on intention-to-treat principle was per-
formed using the Generalized Estimating Equation (GEE),
which has been commonly used for comparisons among
both categorical and continuous variables with or without
normal distribution of scores [44], to examine and com-
pare the mean scores of symptom severity and quality of
life (two sets of ratings of RQLQ-S) and percentages of
four patterns of body constitution (CCMQ) within and
between three groups and across four time measurements
(T1 to T4). Post-hoc (pair-wise) comparisons were then
performed to test any significant differences on the mean
scores of each outcome measure between the three groups
at each of the three post-tests (T2 to T4) if the overall
treatment effect was found significant in the GEE test.
The level of significance of all statistical tests was set
at 5%.
Results
Characteristics of participants at baseline
A total of 249 nursing students with AR were recruited and
nine of them (3.6%) were unable to complete the 4-week
treatment and were lost to follow-up. Therefore, 240 partic-
ipants were finally included in the data analysis (Figure 1).
The main reasons for withdrawal were too busy to fol-
low the treatment regimen (n = 2, 0.8%), parental ob-
jection (n = 3, 1.2%), and experience of discomfort or
mild adverse effects such as increased acne and ab-
dominal distension (n = 4, 1.6%). Ten participants were
unable to complete their treatment but were willing to be
followed-up at post-tests and were therefore included in
the data analysis (based on the intention-to-treat principle).
As indicated in Table 4, the majority of the 240 partici-
pants in the three groups was female (n = 146, 60.8%) and
in Years 1 to 3 (n = 219, 91.3%) of their 4-year undergradu-
ate nursing programmes. Their mean age was 21.30 years
(SD = 1.64), which ranged from 18–25 years. Onset of
AR in childhood was most common and more than
half (n = 149, 62.1%) had AR in primary school or
below. Two-thirds of them experienced attacks of irrit-
able symptoms of AR from daily (n = 68, 28.3%) to sev-
eral times per week (n = 66, 27.5%). More than half did
not receive any kind of treatment for AR (n = 131,
54.6%), while 29 (12.1%) received either Chinese medi-
cine only or both Chinese and Western medicine.
Further, more than half of the participants had a family
history of AR (n = 148, 61.7%). The AR-induced aller-
gens reported by the participants mainly included dust/
polluted air, smoke, hair, mould, and chemicals (e.g., dis-
infectants), and pollen contact was reported by 18 par-
ticipants only (7.5%). Less than half of the participants
(n = 101, 42.1%) also had other allergies such as food
allergies.Homogeneity of the sample in three study groups at
baseline
An assessment of homogeneity of the characteristics
and mean scores of the outcome measures of the three
study groups was performed. As the results indicated
in Table 4, there were no significant differences on the
socio-demographic and clinical characteristics of the
participants between the three study groups (P values
ranged from 0.12 to 0.87). Mean scores (and standard de-
viations) of the outcome measures (CCMQ and RQLQ-S
for both symptom severity and quality of life) at baseline
measurement are summarised in Table 5. There were also
no significant differences on the mean scores of the
three outcome measures between the three study groups
(P values ranged from 0.15 to 0.99), using one-way ana-
lysis of variance test.
Outcome measures at baseline were compared be-
tween groups by using the one-way analysis of variance
(ANOVA) test.
CS, Cure-allergic rhinitis Syrup group; YS, Yu-ping-
feng San syrup group; RQLQ-S, Rhinoconjunctivitis
Quality of Life Questionnaire Standard; CCMQ, Con-
stitution in Chinese Medicine Questionnaire.
Main treatment effects
Results of the interaction (Group × Time) effects using
GEE (Table 6) indicated that there were statistically sig-
nificant differences between the three study groups over
the 3-month follow-up on symptom severity (Wald χ2 =
24.49, P <0.0005; effect size = 0.75), quality of life (Wald
χ2 = 19.47, P = 0.003; effect size = 0.64), and two patterns
of body constitution, including ‘Qi-deficiency’ (Wald χ2 =
15.98, P = 0.01; effect size = 0.40) and ‘Inherited special’
(Wald χ2 = 16.58, P = 0.01; effect size = 0.52). Although
there were no significant interaction effects on the other
two patterns of body constitution (‘Gentleness’ and ‘Yang-
deficiency’), the mean scores in all of the three groups
showed consistent improvements over time (i.e., within-
group effects were statistically significant, Wald χ2 = 99.90
and 137.52 for ‘Gentleness’ and ‘Yang-deficiency’, respec-
tively, and both P values <0.0005).
Post-hoc comparisons of outcome scores at three post-tests
In Table 7, the results of the pairwise contrast tests fol-
lowing the GEE indicated that the CS group reported
significantly greater improvements in:
(a)All four patterns of body constitution than the
placebo (effect sizes range 0.21 to 0.40), including
‘Qi-deficiency’ and ‘Yang-deficiency’ at all post-tests
T2 to T4 (mean difference = −5.70 to −7.87, standard
error [SE] = 2.56 to 2.57, P = 0.01 to 0.002; mean
difference = −6.42 to −8.53, SE = 3.05 to 3.09, P = 0.04
to 0.006, respectively); ‘Inherited special’ at two
Table 4 Demographic and clinical characteristics of participants in the three study groups (n = 240)
Characteristics CS (n = 81) YS (n = 80) Placebo (n = 79) χ2 P
n % n % n %
Gender 2.06 0.36
Male 27 33.33 32 40.00 35 44.30
Female 54 66.67 48 60.00 44 55.70
Age (years) 1.97 0.37
18–22 63 77.78 69 86.25 65 82.28
23–25 18 22.22 11 13.75 14 17.72
Marriage 1.03 0.60
Single 81 100.00 79 98.75 78 98.73
Married 0 0.00 1 1.25 1 1.27
Family income (HK$)a 5.24 0.87
Below 10,000 8 9.88 13 16.25 10 12.66
10,000–19,999 23 28.39 29 36.25 27 34.18
20,000–29,999 23 28.39 22 27.50 23 29.11
30,000–39,000 17 20.99 10 12.50 15 18.99
40,000 or above 10 12.35 3 3.75 4 5.06
Year of study 7.37 0.29
Year 1 25 30.86 32 40.00 21 26.58
Year 2 27 33.33 30 37.50 32 40.51
Year 3 19 23.46 12 15.00 21 26.58
Year 4 10 12.34 6 7.50 5 6.33
Onset of AR 11.92 0.29
Before primary school 23 28.40 20 25.00 24 30.38
Primary school 24 29.63 33 41.25 25 31.65
Secondary school 31 38.27 20 25.00 26 32.91
University 3 3.70 7 8.75 4 5.06
Frequency of AR attack 15.36 0.12
Daily 24 29.63 18 22.50 26 32.91
One to a few weekly 28 34.57 17 21.25 21 26.58
Once to a few monthly 11 13.58 18 22.50 15 18.99
Quarterly 18 22.22 27 33.75 17 21.52
Reasons for AR 17.13 0.51
Allergens 24 29.63 32 40.00 27 34.18
Allergens and cold temperature 57 70.37 48 60.00 52 65.82
History of Medical Treatments used 6.43 0.60
None 42 51.85 48 60.00 41 51.90
Western medicine and/or operation 29 35.80 24 30.00 27 34.18
Chinese medicine 2 2.47 4 5.00 1 12.66
Both Western and Chinese medicine 8 9.88 4 5.00 10 12.66
Family History of AR 14.53 0.41
None 27 33.33 34 42.50 31 39.24
Parent 18 22.22 15 18.75 10 12.66
Sibling 25 30.87 18 22.50 20 25.32
Parents and siblings 11 13.58 13 16.25 18 22.78
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Table 4 Demographic and clinical characteristics of participants in the three study groups (n = 240) (Continued)
Other allergies 10.68 0.71
None 44 55.32 47 58.75 48 60.76
Skin allergy 23 28.40 21 26.25 22 27.85
Food allergy 14 17.28 12 15.00 9 11.39
CS, Cure-allergic-rhinitis Syrup group; YS, Yu-ping-feng San group; AR, Allergic rhinitis.
aUS$1 = HK$7.8.
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and −7.14, SE = 2.44 and 2.45, P = 0.03 and 0.003,
respectively); and ‘Gentleness’ at T2 and T3 (mean
difference = 6.18 and 5.93, both SE values = 1.99,
P = 0.002 and 0.003, respectively).
(b)Symptom severity than the placebo (mean difference =
−26.13 to −34.54, all SE values = 7.59, P = 0.001 to
<0.0005) at T2 to T4 (effect sizes range 0.51 to 0.73);
whereas, no significant differences with those in the
YS group across the three post-tests.
(c)Quality of life than the placebo (mean difference =
−12.81 to –16.76, all SE values = 3.96, P = 0.001 to
<0.0005) at T2 to T4 (effect sizes range 0.50 to
0.64); whereas, there were no significance differences
with those in the YS across the three post-tests.
In addition, the CS group also indicated significantly
greater improvements in all of the seven domains of
symptom severity (Table 8), including activities, sleep,
non-nose/non-eye symptoms, practical problems, nasal
symptoms, eye symptoms, and emotional functions, than
the placebo group at T2 to T4 (mean difference = −2.04
to −7.95, SE = 0.95 to 2.13, P = 0.04 - <0.0005; mean
difference = −3.01 to −8.88, SE = 0.95 to 2.13, P = 0.008
to <0.0005; mean difference = −3.52 to −7.76, SE = 0.95 -
2.13, P = 0.004 to <0.0005, respectively). However, there
were consistent but non-significantly greater improve-
ments in all these domains of symptoms in the CS com-
pared to those in the YS group (P = 0.99 to 0.11).Table 5 Comparison of mean scores of symptom severity, qua
three groups (n = 240)
CS (n = 81) YS (n = 8
Variables Mean SD Mean
RQLQ-S – Symptom severity 102.93 45.04 101.59
CCMQ
Gentleness 55.31 12.25 53.47
Qi-deficiency 42.85 15.95 39.56
Yang-deficiency 38.25 20.98 39.36
Inherited special 41.07 15.09 39.77
RQLQ-S – Quality of life 59.73 23.86 58.91As shown in Tables 7 and 8, the YS group reported
significantly greater improvements in the overall and
four domains of symptom severity at T2 to T4 (effect
sizes ranged 0.22 to 0.41) than the placebo group, includ-
ing total score (mean difference = −20.85 to −27.07, all
SEs = 7.61, P = 0.006 to <0.0005), activities (mean differ-
ence = −3.03 to −3.83, all SEs = 0.95, P = 0.003 to 0.001),
non-nose/non-eye symptoms (mean difference = −5.26
to −6.41, all SEs = 2.13, P = 0.01 to 0.003), practical
problems (mean difference = −2.72 to −3.97, all SEs =
1.17, P = 0.02 to 0.001), and nasal (mean difference = −3.20
to −4.52, all SEs = 1.44, P = 0.03 to 0.002). The YS group
also showed significantly greater improvements in the
domains of emotional function at T3 and T4 (mean
difference = −2.91 and −3.12, both SEs = 1.15, P = 0.01
and 0.007), and sleep (mean difference = −2.60, SE = 0.97,
P = 0.007) and eye symptoms (mean difference = −2.61,
SE = 1.22, P = 0.03) at T4, when compared to the placebo
group (effect sizes ranged 0.29 to 0.37).
For the current usage of Western medicine, a total of
62 participants (25.8%) received one to a few types of
Western medicine for treatment of AR according to doc-
tors’ prescription or over-the-counter medications (n =
30 in CS; n = 15 in YS; and n = 17 in placebo) before this
trial. However, there was a significant reduction of such
medication use in both the CS (n = 1) and YS (n = 3)
groups over the 3-month follow-up; whereas, there were
only slight changes in medication use among the placebo
controls (i.e., n = 14 over follow-up).lity of life and body constitution at baseline between
0) Placebo (n = 79) ANOVA
SD Mean SD F P
49.35 105.93 46.84 0.18 0.84
12.02 52.42 12.98 0.64 0.53
16.93 44.83 15.24 1.92 0.15
20.48 42.32 18.16 0.74 0.48
14.93 39.86 17.15 0.02 0.99
26.85 60.87 23.70 0.13 0.88
Table 6 Results on symptom severity, quality of life, and body constitution in the three groups at four measurements and comparisons using GEE (n = 240)
CS (n = 81) YS (n = 80) Placebo (n = 79) GEE (Group ×
Time)T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 T3 T4
Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean Mean
(SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) Wald χ2 P
SS total score 102.93 (5.33) 61.21 (5.33) 51.42 (5.33) 42.29 (5.33) 101.59 (5.37) 66.49 (5.37) 62.21 (5.37) 49.76 (5.37) 105.93 (5.40) 87.34 (5.40) 84.06 (5.40) 76.83 (5.40) 24.49 <0.0005
QOL total score 59.73 (2.78) 37.54 (2.78) 32.56 (2.78) 29.22 (2.78) 58.91 (2.80) 41.78 (2.80) 37.86 (2.80) 33.34 (2.80) 60.87 (2.82) 50.35 (2.82) 49.32 (2.82) 45.08 (2.82) 19.47 0.003
Body constitution
Gentleness 55.31 (1.40) 60.90 (1.40) 61.99 (1.40) 61.91 (1.40) 53.47 (1.40) 57.73 (1.42) 59.15 (1.41) 60.64 (1.41) 52.42 (1.41) 54.72 (1.42) 56.06 (1.42) 59.97 (1.42) 9.02 0.17
Qi-deficiency 42.85 (1.80) 35.05 (1.80) 33.58 (1.80) 33.57 (1.80) 39.56 (1.80) 37.50 (1.82) 36.43 (1.82) 34.82 (1.82) 44.83 (1.81) 42.92 (1.83) 40.05 (1.83) 39.27 (1.82) 15.98 0.01
Yang-deficiency 38.25 (2.13) 29.46 (2.17) 28.57 (2.17) 28.26 (2.15) 39.36 (2.16) 34.54 (2.19) 33.96 (2.19) 33.29 (2.16) 42.32 (2.16) 37.99 (2.18) 34.99 (2.19) 35.17 (2.17) 6.75 0.35
Inherited special 41.07 (1.71) 32.43 (1.72) 31.33 (1.71) 29.36 (1.71) 39.77 (1.72) 34.37 (1.74) 32.13 (1.73) 32.09 (1.73) 39.86 (1.73) 37.65 (1.74) 33.91 (1.74) 36.49 (1.74) 16.58 0.01
SS, Symptom severity; QOL, Quality of life; CS, Cure-allergic-rhinitis Syrup group; YS, Yu-ping-feng San group; GEE, Generalised Estimating Equation test.

















Table 7 Contrast tests of mean score differences on symptom severity, quality of life, and four patterns of body constitution at three post-tests (n = 240)
RQLQ-S for SS RQLQ-S for QOL Gentleness Qi-deficiency Yang-deficiency Inherited special
Slope MD Slope MD Slope MD Slope MD Slope MD Slope MD
(SE) (P) (SE) (P) (SE) (P) (SE) (P) (SE) (P) (SE) (P)
T2
CS vs. placebo 23.12 (7.59) −26.13 (0.001) 11.67 (3.96) −12.81 (0.001) −3.29 (1.99) 6.18 (0.002) 5.88 (2.56) −7.87 (0.002) 4.45 (3.08) −8.53 (0.006) 6.43 (2.45) −5.22 (0.03)
CS vs. YS 6.61 (7.57) −5.28 (0.49) 5.05 (3.95) −4.23 (0.28) −1.32 (1.99) 3.16 (0.11) 5.74 (2.56) −2.46 (0.34) 3.97 (3.08) −5.08 (0.10) 3.24 (2.44) −1.94 (0.43)
YS vs. placebo 2.33 (7.61) −20.85 (0.006) 2.05 (3.97) −8.58 (0.03) −1.97 (2.01) 3.01 (0.13) 0.14(2.58) −5.41 (0.04) 0.48 (3.09) −3.45 (0.27) 3.19 (2.46) −3.27 (0.18)
T3
CS vs. placebo 29.64 (7.59) −32.64 (<0.0005) 15.61 (3.96) −16.76 (<0.0005) −3.03 (1.99) 5.93 (0.003) 4.49 (2.57) −6.47 (0.01) 2.35 (3.09) −6.42 (0.04) 3.79 (2.45) −2.58 (0.29)
CS vs. YS 12.12 (7.57) −10.79 (0.15) 6.12 (3.95) −5.31 (0.18) −1.00 (1.99) 2.84 (0.15) 6.14 (2.56) −2.85 (0.26) 4.29 (3.09) −5.40 (0.08) 2.09 (2.44) −0.80 (0.74)
YS vs. placebo 2.12 (7.61) −21.85 (0.004) 2.75 (3.98) −11.46 (0.004) −2.03 (2.00) 3.09 (0.12) −1.65 (2.58) −3.62 (0.16) −1.94 (3.10) −1.03 (0.74) 1.70 (2.46) −1.78 (0.47)
T4
CS vs. placebo 31.54 (7.59) −34.54 (<0.0005) 14.71 (3.96) −15.86 (<0.0005) 0.95 (1.99) 1.95 (0.33) 3.71 (2.56) −5.70 (0.03) 2.83 (3.05) −6.90 (0.02) 8.35 (2.44) −7.14 (0.003)
CS vs. YS 8.80 (7.57) −7.47 (0.32) 4.93 (3.94) −4.11 (0.30) 0.57 (1.99) 1.27 (0.52) 4.54 (2.56) −1.27 (0.62) 3.92 (3.04) −5.03 (0.10) 4.03 (2.44) −2.73 (0.26)
YS vs. placebo 2.93 (7.61) −27.07 (<0.0005) 2.97 (3.97) −11.74 (0.003) 0.38 (2.00) 0.67 (0.74) −0.83 (2.57) −4.44 (0.08) −1.09 (3.06) −1.87 (0.54) 4.32 (2.45) −4.40 (0.07)
RQLQ-S, Rhinoconjunctivitis Quality of Life Questionnaire Standard; SS, Symptom severity; QOL, Quality of life; CS, Cure-allergic-rhinitis Syrup group; YS, Yu-ping-feng San group MD, Mean difference between two
groups; SE, Standard error in Generalised Estimating Equation (GEE) test.

















Table 8 Contrast tests of mean scores of seven domains of symptom severity (in RQLQ-S) between groups at three post-tests (n = 240)
Activities Sleep Non-nose/non-eye
symptoms
Practical problems Nasal symptoms Eye symptoms Emotional
Slope MD Slope MD Slope MD Slope MD Slope MD Slope MD Slope MD
(SE) (P) (SE) (P) (SE) (P) (SE) (P) (SE) (P) (SE) (P) (SE) (P)
T2
CS vs. placebo 2.02 (0.95) −2.86 (0.004) 1.78 (0.96) −2.04 (0.04) 6.39 (2.13) −7.95 (<0.0005) 3.77 (1.17) −3.21 (0.006) 3.43 (1.43) −3.49 (0.02) 2.93 (1.21) −2.90 (0.02) 2.80 (1.15) −3.67 (0.001)
CS vs. YS −0.31 (0.95) −0.38 (0.69) 0.47 (0.96) −0.30 (0.76) 2.95 (2.12) −2.69 (0.20) 1.10 (1.17) −0.49 (0.68) 0.69 (1.43) −0.02 (0.99) 0.96 (1.21) −0.69 (0.57) 0.75 (1.15) −1.47 (0.20)
YS vs. placebo 2.33 (0.95) −3.24 (0.002) 1.31 (0.97) −1.74 (0.07) 3.44 (2.13) −5.26 (0.01) 2.68 (1.17) −2.72 (0.02) 2.745 (1.44) −3.47 (0.02) 1.98 (1.22) −2.22 (0.07) 2.05 (1.15) −2.20 (0.06)
T3
CS vs. placebo 2.93 (0.95) −3.76 (0.001) 2.75 (0.96) −3.01 (0.002) 7.32 (2.13) −8.88 (<0.0005) 4.87 (1.17) −4.31 (<0.0005) 5.44 (1.43) −5.50 (<0.0005) 3.22 (1.21) −3.20 (0.008) 3.01 (1.15) −3.97 (0.001)
CS vs. YS 0.81 (0.95) −0.74 (0.44) 1.38 (0.96) −1.21 (0.21) 3.08 (2.12) −2.82 (0.18) 2.07 (1.17) −1.46 (0.21) 2.98 (1.43) −2.30 (0.11) 1.47 (1.21) −1.20 (0.32) 0.35 (1.15) −1.06 (0.36)
YS vs. placebo 2.12 (0.95) −3.03 (0.003) 1.38 (0.97) −1.80 (0.06) 4.24 (2.13) −6.06 (0.004) 2.81 (1.17) −2.85 (0.02) 2.47 (1.44) −3.20 (0.03) 1.76 (1.22) −2.00 (0.10) 2.76 (1.15) −2.91 (0.01)
T4
CS vs. placebo 3.18 (0.95) −4.01 (<0.0005) 3.47 (0.96) −3.73 (<0.0005) 6.20 (2.13) −7.76 (<0.0005) 5.29 (1.17) −4.73 (<0.0005) 6.70 (1.43) −6.76 (<0.0005) 3.55 (1.21) −3.52 (0.004) 3.17 (1.15) −4.04 (<0.0005)
CS vs. YS 0.25 (0.95) −0.18 (0.85) 1.29 (0.96) −1.13 (0.24) 1.61 (2.12) −1.35 (0.53) 1.37 (1.17) −0.76 (0.52) 2.91 (1.43) −2.24 (0.12) 1.18 (1.21) −0.91 (0.70) 0.19 (1.15) −0.91 (0.43)
YS vs. placebo 2.93 (0.95) −3.83 (0.001) 2.18 (0.97) −2.60 (0.007) 4.59 (2.13) −6.41 (0.003) 3.92 (1.17) −3.97 (0.001) 3.79 (1.44) −4.52 (0.002) 2.36 (1.22) −2.61 (0.03) 2.97 (1.15) −3.12 (0.007)
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The findings of this study are encouraging to support
the positive effects of Chinese herbal medicinal formula
Cure-Allergic Rhinitis Syrup [治敏膏] (CS) when treat-
ing young adults (nursing students) with AR. The CS
was found to significantly improve the nursing students’
symptom severity, body constitution, and quality of life
over the 3-month follow-up. The findings demonstrated
that an application of herbal medicine with ‘Hot’ and
‘Qi’ (and ‘Yang’) rectifying nature, that was the CS tested
in this trial, could strengthen functions of the ‘Lung’
(respiratory organ) and ‘Spleen’ (digestive organ), as
well as the ‘Kidney’ (excretory organ), thus alleviating
the symptoms of AR [27,28]. Over the 3-month follow-
up, the ‘Qi-deficiency’, ‘Yang-deficiency’, and ‘Inherit
special’ (i.e., the inherited entities that guide one’s body
development and formation of special characters such
as allergic reactions) patterns of body constitution
were much improved, while the ‘Gentleness’ (healthy)
body constitution had increasingly strengthened, when
compared to the placebo group. Overall, most of these
significant effects (‘Qi-deficiency’, ‘Yang-deficiency’,
and ‘Inherit special’) in the CS group could also be ob-
tained much earlier and last longer than those in the
YS group. As supported by the theories of CM, the CS
could facilitate the balance between ‘Yin’ and ‘Yang’ by
regulating or rectifying ‘Qi’ flowing inside the body
and thus relieve the deficiency of ‘Yang’, which kept
motivating the functions of the internal organs and
produce energy in the body parts [45].
The participants in this trial, similar to most people
with AR, presented with subnormal regulation of ther-
mal and/or body defence conditions, which was innate
to human beings [46]. They might require for the herbal
medicine (i.e., the CS), or other regulatory forces, to
strengthen or enhance their ‘Qi’ to drive the whole body
(body organs and systems) to keep warm, maintain a
good immune defence, and promote the internal regula-
tory mechanisms [47]. The majority of AR sufferers, like
the nursing students in this trial, have syndromes (‘Zheng’)
of ‘Qi-deficiency’ and/or ‘Yang-deficiency’ with ‘Cold’ or
‘flu’ like symptoms such as running nose and nasal con-
gestion. These could be treated by using herbal medicines
with ‘Hot’ or ‘Warm’ in nature, which were particularly
useful to regulate the malfunctions of the respiratory
(‘Lung’) and digestive (‘Spleen’) systems, and even excre-
tory (‘Kidney’) organs [45,46].
The findings also provided evidence on the signifi-
cance of prescription of Chinese herbal medicines based
on assessment results of syndrome (‘Zheng’) and body
constitution, which reflected the structure, metabolism,
and functioning of the main body organs that contrib-
uted to determining one’s susceptibility to pathogenic
factors [14,15]. All participants in this trial were assessedby a CM practitioner to confirm their ‘Qi-deficiency’
and/or ‘Yang-deficiency’ before being included in this
study and provided them with the CS or YS. Accurate
prescription of medicine based on accurate ‘Zheng’ dif-
ferentiation can assure or enhance its therapeutic or
curative effects to an illness. On the other hand, neglect-
ing the syndrome differentiation or misinterpreting the
body constitution may result in inappropriate treatment
prescription, thus causing unsatisfactory or even harmful
and adverse effects to treatment recipients. Only four
patients (1.6%) in this trial reported adverse effects,
which was much lower than other clinical trials of herbal
medicinal treatment of AR without ‘Zheng’ identifica-
tion, for example, about 21% in Xue et al.’s [19] study.
In addition, this trial reported a low attrition rate (n = 9,
3.6%), in which only one participant in the CS group was
unable to complete the 4-week treatment and was lost to
follow-up. As patterns of body constitution signify the re-
actions of the body to specific pathogen(s), the partici-
pants (nursing students) with AR who were unable to
keep warm and satisfactory immune defences had devel-
oped hypersensitive reactions to those allergens, thus
resulting in main symptoms of AR [46,48]. It is note-
worthy that two strategies adopted in this trial might fa-
cilitate the participants’ completion of their treatments,
including regular consultation and assessment of their
health condition during the treatment period and the use
of medication in syrup format which was considered more
user-friendly, with a better taste and more accurate dosage
than conventional administration of herbal medicine.
Therefore, the 4-week CS treatment was found to be more
consistent and have substantive therapeutic effects on pa-
tient outcomes than other clinical trials of herbal medi-
cinal treatment of AR [15,17-21]. Nevertheless, future
research in a large-sized, representative sample with di-
verse socio-demographic and illness-related characteristics
(e.g., wider age ranges, living environments, and family
medical history), and a longer-term follow-up (e.g., one
year), is recommended to examine a more consistent and
conclusive curative effect of the CS before its application
for usual treatment.
Yu-ping-feng San [玉屏風散] (YS), which contained
six Chinese herbs (plus sugar and wheat flour) com-
monly used for treatment of AR in recent CM studies
[22,23], was adopted to be the alternative medicinal
treatment in this trial. The results indicated its small to
moderate effects on improving the participants in their
symptom severity, quality of life, and one to two patterns
of body constitution over the 3-month follow-up. When
compared to the CS group, the participants in the YS
group showed less prominent and substantive effects on
the main treatment outcomes, particularly their body
constitution. The YS has been used in recent clinical tri-
als of AR to strengthen the ‘Qi’, allaying nasal symptoms
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sions, but not including the ‘Kidney’ organ [32-34,49,50].
Therefore, the YS might not be able to fully reinforce and
rectify the ‘Qi-Yang’ in the three target organs, thus being
inadequate to minimise the symptoms of AR or cure AR
in the long term, as the CS did.
Limitations and future research
A few limitations of this study were found. First, the
sample that was a group of nursing students voluntarily
participated (i.e., <20% of the eligible subjects) and re-
cruited from only one of the three universities in Hong
Kong. The findings, although promising, might not be
generalizable to other Chinese young adults or different
age groups with AR. The participants might also be highly
motivated for treatment due to their nursing background.
Second, risk factors influencing symptoms of AR could
not be similar between different years of nursing study, for
example, there were relatively much longer periods of
clinical placement among those senior students who
would therefore be more frequently exposed to disinfec-
tants and other allergens in hospitals and other clinical
units. Third, this study adopted a 3-month follow-up
period. Only about 12-16% of them (n = 10-13) in the
CS group indicated an absence of Qi-deficiency, Yang-
deficiency, and Inherited special BC at the post-tests
T2- T4. AR is an enduring and distressing chronic ill-
ness, the substantive effect of herbal medicine used to
cure and prevent reoccurrence of the illness should be
examined with a longer term follow-up (e.g., >1 year).
However, the ideal of a double-blind, randomised con-
trolled trial could be achieved due to the complete con-
cealment of the participants and research team to the
treatment assignment and very similar study procedure
and spicy and syrup form of medications. However, it is
recommended to explore the perceived benefits and lim-
itations of the treatment experienced from the perspec-
tive of the participants in order to better understand the
treatment procedure, progress, and strengths of the treat-
ment offered, as well as its room for improvement.
Future research can include other outcome measures
used in Western medicine such as the blood test for IgE
and skin sensitivity tests for allergens to confirm and/or
compare the clinical efficacy of the Chinese herbal medi-
cine used across studies. Furthermore, research to com-
pare the relative clinical efficacy between the CS and
other approaches to Chinese and/or Western medicine
or complementary and alternative therapies, such as
dietary and massage therapy, on a wide variety of patient
outcomes can be considered.
Conclusions
This double-blind randomised controlled trial demon-
strated that the herbal medicinal formula CS could beeffective in Chinese young adults (nursing students) with
AR and ‘Yang- and/or Qi-deficiency’ patterns of body
constitution (or ‘Zheng’). The herbal medicines in syrup
form were found to be user-friendly and useful to signifi-
cantly reduce the participants’ symptoms of AR and im-
prove their body constitution and quality of life over
three months of follow-up. The findings also suggest
that the syndrome differentiation facilitated the accurate
treatment prescription, making the herbal medicine used
more appropriate to the patients, thus resulting in sig-
nificantly better therapeutic or curative effects. Further
research is recommended to test the clinical efficacy of
the CS in diverse patient populations and a long-term
follow-up to confirm its curative function in the treat-
ment of allergic rhinitis.
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